Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Article in Nature Communications (March 2024)
The most recent citing publications are shown below. View all 78 publications that cite this research output on Dimensions.
Article in Nature Communications (March 2024)
Preprint in medRxiv (December 2023)
Article in Cancer Immunology, Immunotherapy (October 2023)